$诺诚健华-B(09969)$ $赛诺菲-安万特(SNY)$
SNY的Tolebrutinib clinical trial program update停留在8月8号，几个III期的自免适应症中，RMS的两个III期，fully enrolled and on track for a 2024 FDA submission in the U.S；
MG/PPMS/nrSPMS的III期，work to remove the partial clinical hold in Q4 2022.
| 发布于: | 雪球 | 转发：2 | 回复：3 | 喜欢：1 |
$诺诚健华-B(09969)$ $赛诺菲-安万特(SNY)$
SNY的Tolebrutinib clinical trial program update停留在8月8号，几个III期的自免适应症中，RMS的两个III期，fully enrolled and on track for a 2024 FDA submission in the U.S；
MG/PPMS/nrSPMS的III期，work to remove the partial clinical hold in Q4 2022.
A phase 3 trial in non-relapsing secondary progressive multiple sclerosis hit its recruitment target late last year. Sanofi is continuing to recruit patients for its primary progressive multiple sclerosis trial outside of the U.S.
At the time, Sanofi outlined plans to get the FDA partial clinical hold lifted in the fourth quarter but has now decided to walk away from myasthenia gravis while continuing to advance tolebrutinib in multiple sclerosis. In a full-year earnings document this morning, Sanofi said it reached the decision after a “careful evaluation of the emerging competitive treatment landscape.”
取消MG的III期临床，继续推进MS
图片评论